key: cord-0790282-zlc0dv0a
authors: Katsiki, Niki; Banach, Maciej; Mikhailidis, Dimitri P.
title: Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic
date: 2020-04-14
journal: Arch Med Sci
DOI: 10.5114/aoms.2020.94503
sha: 8579fe8c655930cafc2c230d8c4f6fe7b55d7c47
doc_id: 790282
cord_uid: zlc0dv0a

nan

The novel coronavirus (severe acute respiratory syndrome coronavirus 2 -SARS-Cov-2) disease 2019 (COVID- 19) pandemic has been associated with severe respiratory disease incidence and increased mortality [1] . Angiotensin converting enzyme (ACE) 2 is a homologue of ACE, but also a receptor for the coronaviruses [2] . ACE2 is highly expressed in the lungs, heart, gastrointestinal (GI) tract and kidney, thus affecting the cardiovascular system (CV) and the immune system [3] . The overexpression of ACE2 was reported to enhance viral entry and replication intracellularly [4] . COVID-19, also called SARS-CoV-2, may also use ACE2 as a receptor to initiate infection, leading to severe complications from the heart (acute coronary syndrome (ACS) and fulminant myocarditis), lungs (pneumonia and acute respiratory distress syndrome (ARDS)) and GI tract (diarrhoea syndrome) [5] .

ACE2 gene expression is affected by several factors, including gender (ACE2 gene is X-linked), ACE2 gene polymorphisms, comorbidities (increased in the presence of CVD, hypertension, diabetes), and drug therapy [6] . With regard to drugs, angiotensin II receptor blockers (ARBs) and mineralocorticoid receptor antagonists (MRA) have been reported to raise ACE2 activity in human and animal studies [7] . There are only a few animal studies available showing that statins may also increase ACE2 activity [8, 9] . In the era of the COVID-19 pandemic, such a drug effect may be considered as potentially worrying [10] . In this context, it was recently even suggested that ARBs could be replaced with ACE inhibitors and that statin treatment may be discontinued during the pandemic, particularly in primary prevention settings [11] .

However, before implementing such strategies, we should consider several issues. Firstly, as the COVID-19 infection progresses, ACE2 is downregulated, thus potentially generating an inflammatory response leading to impaired cardiac contractility and acute lung injury [5, 7, 12] . Therefore, reduced ACE2 expression is linked to worse outcomes. On the other hand, ACE2 overexpression has been associated with several beneficial effects, i.e. prevention of adverse cardiac remodelling and fibrosis, improvement of vascular endothelial dysfunction, reduction of blood pressure, and protection from ARDS [7, 12] . Both statins and ARBs were reported to exert these benefits.

Secondly, a combination of statins/ARBs were used during the 2014 Ebola virus disease epidemic in Sierra Leone, leading to improved outcomes and increased survival [13] . These drugs can affect the host response to infection, not the virus, especially by preventing endothelial dysfunction, a shared feature of several virus infections [14] . Their combination seemed to promote a return to homeostasis, allowing patients with Ebola virus infection to recover on their own [15] .

Third, patients with cardiovascular disease (CVD) were shown to be more prone to COVID-19 infection and with worse prognosis [16, 17] . Elevated inflammatory markers, such as C-reactive protein (CRP) and interleukin-6 (IL-6), have been recognised as predictors of COVID-19 infection severity and mortality, suggesting a virus-activated "cytokine storm syndrome" [18, 19] . Therefore, as well as immunomodulation, COVID-19 treatment should also target reduction of inflammation. In this context, statins have been consistently reported to exert immunomodulatory and anti-inflammatory properties [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] . Also, it was previously suggested that statins could enhance host defence and suppress inflammation, thus representing a practical and inexpensive adjunctive or alternative host-directed treatment for infections by viruses, fungi, protozoa, and bacteria [31] . Similarly, there are data supporting an anti-inflammatory role for ARBs [32] [33] [34] .

Fourth, statins may also prevent a viral-induced acute coronary syndrome (also in COVID-19 positive patients) by stabilising atherosclerotic plaques [35] , as well as prevent acute kidney injury (AKI) [36] . Both acute cardiac injury and AKI are predictors of COVID-19-induced mortality [37] ; statin therapy may prevent these complications and thus increase survival. Of note, statins can protect against contrast-induced AKI (CI-AKI) [38] [39] [40] [41] . This is of clinical importance, especially in hospitalised patients who undergo diagnostic or therapeutic procedures involving the administration of contrast media (e.g. computed tomography of the lungs).

Fifth, effective lipid-lowering therapy (LLT) and significant cholesterol reduction might significantly suppress coronavirus infection. It was show that for infectious bronchitis virus (IBV) coronavirus, drug-related cholesterol reduction disrupts lipid rafts (an important element for the cellular entry of coronavirus) that enable the binding of the coronavirus with the host cells and, consequently, further infection [42] . It was also observed, in the studies with porcine deltacoronavirus (PDCoV), that cholesterol present in the cell membrane and viral envelope (coronaviruses are positive-sense enveloped RNA viruses) contributes to PDCoV replication by acting as a key component in viral entry. Thus, the pharmacological sequestration of cellular or viral cholesterol with effective LLT significantly blocked both virus attachment and internalisation [43] . All these mechanisms might suggest a critical role of statins and LLTs in the inhibition of coronavirus infection.

In COVID-19-positive patients, the majority of baseline CVD is of atherosclerosis origin, with the worst prognosis for patients being at the high, and especially very high and extremely high, risk of CVD [16] ; thus, intensive LLT with statins and/or fixed combination with ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors seems to be critical. Indeed, we should do our best to maximally improve therapy adherence and thus have a better prognosis for the infected CVD patients [44, 45] . In this context, there are no premises that PCSK9 inhibitors, because they are monoclonal antibodies (in relation to the above-mentioned high cytokine storm during infection), should be discontinued. In contrast, PCSK9 inhibitors should be continued to achieve further low-density lipoprotein cholesterol (LDL-C) lowering (based on "the lower, the better" principle), because then we might significantly stabilise atheroma plaque, reduce the risk of CVD events, and reduce inflammation [46] [47] [48] . Recent available data have confirmed the role of PCSK9 inhibition in reducing the process of inflammation via decreasing main vascular inflammatory markers, reducing infiltration of monocytes into the subendothelial layer, and inhibiting monocyte migration. Apart from the reduction of pro-inflammatory mediators, PCSK9 inhibitors could ameliorate vascular inflammation [47] . Finally, a direct local anti-inflammatory action of PCSK9 inhibitors, independent of LDL-C reduction, has been shown in animal models; however, it still merits further investigation [47, 48] .

It is of special interest now (due to the fact that coronavirus might also use different receptors to enter the host cell) that treatment with PCSK9 inhibitors has beneficial effects on LDL-C lowering via inhibition of LDL-receptors (LDL-R). This might exert an antiviral effect, among others, on hepatitis C viral (HCV) infection through down-regulation of the surface expression of LDL-R and cluster of differentiation (CD) 81 on hepatic cells, and a positive association with increased inflammatory responses, as well as with septic shock [48] . In a recent paper, we confirmed that there is no association between PCSK9 levels and resistance to antibiotics or the condition of patients hospitalised in intensive care units, a finding of clinical importance in the COVID-19 infection era [49] .

Sixth, there are conflicting results regarding the possible effects of statins on ARDS development and outcomes [50, 51] . It was suggested that statins act beneficially in 'hyper-inflammatory' ARDS patients (defined by increased biomarkers of inflammation, coagulation and endothelial activation) [52] , but not in 'hypo-inflammatory' patients [53, 54] . A potential benefit of ARBs on survival in ARDS patients has also been reported [55, 56] . Nevertheless, there is a paucity of data on this field, and thus further research is needed to elucidate the association between statin therapy, ARBs, and acute lung injury.

Of note, drug-drug interactions should also be considered. In this context, simvastatin and lovastatin are contraindicated in patients on lopinavir/ ritonavir therapy due to an increased risk of rhabdomyolysis [57] . Atorvastatin, rosuvastatin and other statins can be used at the lowest possible dose, based on the instructions included in the summary of product characteristics (spc) [58] . Taking this into account, we should be careful while treating COVID-19 disease patients with statins being on antiviral drugs and some antibiotics (including macrolides), because they might increase the risk of statin-associated muscle symptoms (SAMS) [59, 60] . Therefore, their careful monitoring is highly recommended to avoid unnecessary drug-related side effects, and at the same time optimising LLT therapy to achieve the individual's LDL-C goal. In this context, in patients at very high CVD risk, requiring intensive LLT, it is reasonable to initiate therapy with polypills/fixed combinations of statins (at lower doses) and ezetimibe, with or without PCSK9 inhibitors (as available), aimed at reducing the risk of SAMS [59, 60] .

A position statement of the European Society (ESC) Council (on 13 March 2020) (as well as of other national and international societies) highlights the lack of evidence on harmful effects of ACE inhibitors and ARBs on the incidence and progression of COVID-19 infection and strongly supports the continuation of usual antihypertensive therapy [6, 61] . Regarding statins, their beneficial effects on inflammation, vascular, heart, and lung function strongly support the continuation of their use. Due to their significant effect on CVD prevention, PCSK9 inhibitors should also be continued, as available. Physicians should wait for strong evidence and recommendations from international scientific societies before altering their patients' drug therapy in the COVID-19 era.

Dr Niki Katsiki and Maciej Banach contributed equally to this paper.

NK has given talks, attended conferences, and participated in trials sponsored by Angelini, Astra Zeneca, Bausch Health, Boehringer Ingelheim, Elpen, Mylan, NovoNordisk, Sanofi, and Servier. MB -speakers bureau: Abbott/Mylan, Abbott Vascular, Actavis, Akcea, Amgen, Biofarm, KRKA, MSD, Polpharma, Sanofi-Aventis, Servier and Valeant; consultant to Abbott Vascular, Akcea, Amgen, Daichii Sankyo, Esperion, Freia Pharmaceuticals, Lilly, MSD, Polfarmex, Resverlogix, Sanofi-Aventis; Grants from Sanofi and Valeant. DPM has given talks and attended conferences sponsored by Amgen, Novonordisk, and Libytec.

R e f e r e n c e s

Epidemiology of Covid-19 in a long-term care facility in King County, Washington

The two fACEs of the tissue renin-angiotensin systems: implication in cardiovascular diseases

ACE2: from vasopeptidase to SARS virus receptor

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Is there an association between COVID-19 mortality and the renin-angiotensin system-a call for epidemiologic investigations

Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19

Angiotensin-converting enzyme 2 as a therapeutic target for heart failure

Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats

Influence of atorvastatin on angiotensin I metabolism in resting and TNF-alpha-activated rat vascular smooth muscle cells

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19

Are certain drugs associated with enhanced mortality in COVID-19?

Recombinant human ACE2: acing out angiotensin II in ARDS therapy

Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola

Do viral infections mimic bacterial sepsis? The role of microvascular permeability: a review of mechanisms and methods

Hiding in plain sight: an approach to treating patients with severe COVID-19 infection

Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical features and treatment of COVID-19 patients in Northeast Chongqing

Statins, the renin-angiotensin-aldosterone system and hypertension -a tale of another beneficial effect of statins

Lipids, statins and heart failure: an update

The role of statins in the treatment of type 2 diabetes mellitus: an update

Improvement of endothelial function by pitavastatin: a meta-analysis

Immune modulatory effects of statins

Clinician's guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week

Effect of statin therapy on arterial wall inflammation based on 18F-FDG PET/CT: a systematic review and meta-analysis of interventional studies

Effect of statins on toll-like receptors: a new insight to pleiotropic effects

Sahbekar A. Modulation of heat shock proteins by statins

Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials

The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy: 5-year follow-up

Statins: a viable candidate for host-directed therapy against infectious diseases

Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation

Effect of different classes of antihypertensive drugs on endothelial function and inflammation

The effect of angiotensin receptor blockers on C-reactive protein and other circulating inflammatory indices in man

Potential effects of coronaviruses on the cardiovascular system: a review

Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Contrast-induced acute kidney injury: beware of the risk after coronary angiography

Contrast-induced acute kidney injury in diabetes mellitus: clinical relevance and predisposing factors. Could statins be of benefit?

Contrast-Induced nephropathy: an "all or none" phenomenon?

Pleiotropic effects of statins: untapped potential for statin pharmacotherapy

The important role of lipid raft-mediated attachment in the infection of cultured cells by coronavirus infectious bronchitis virus beaudette strain

Cholesterol is important for the entry process of porcine deltacoronavirus

Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement

Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?

PCSK9 and inflammation: a review of experimental and clinical evidence

PCSK9 and infection: a potentially useful or dangerous association?

Association of serum PCSK9 levels with antibiotic resistance and severity of disease in patients with bacterial infections admitted to intensive care units

Simvastatin in the acute respiratory distress syndrome

Rosuvastatin for sepsis-associated acute respiratory distress syndrome

MARS consortium. Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis

Targeted treatment of acute respiratory distress syndrome with statins -a commentary on two phenotype stratified re-analysis of randomized controlled trials

Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial

Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study. Korean

Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome

Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic

Optimizing cholesterol treatment in patients with muscle complaints

Statin intolerancean attempt at a unified definition. Position paper from an International Lipid Expert Panel